Skip to content

Effect of semaglutide on depression in patients with type 2 diabetes mellitus in the plateau: A single-center, prospective cohort study

Effect of semaglutide on depression in patients with type 2 diabetes mellitus in the plateau: A single-center, prospective cohort study

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400084738
Enrollment
Unknown
Registered
2024-05-23
Start date
2024-07-01
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes

Interventions

Semaglutide:None
Non-Semaglutide:None

Sponsors

Tibet Autonomous Region People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Exposed group 1. =18 years old and =75 years old; 2. Diagnosed with type 2 diabetes; 3. Oral hypoglycemic agents, insulin, semaglutaide or a combination of boths; 4. HbA1c=7% and =15%; 5. Permanent residence in Lhasa for 6 months or more (altitude of 3650 m); Non-exposed group 1. =18 years old and =75 years old; 2. Diagnosed with type 2 diabetes; 3. Oral hypoglycemic agents, insulin or a combination of boths; 4. HbA1c=7% and =15%; 5. Permanent residence in Lhasa for 6 months or more (altitude of 3650 m);

Exclusion criteria

Exclusion criteria: 1. Present with diabetic ketoacidosis or diabetic hyperosmosis; 2. A medical or family history of medullary thyroid carcinoma, multiple endocrine adenomatosis type 2A or 2B; 3. Had a history of gastroparesis, uncontrolled gastroesophageal reflux disease, and gastric ulcer within 6 months before enrollment, including persistent nausea and vomiting; 4. Has serious disease of the cardiovascular, liver, endocrine, or other systems that prevents the completion of the study or affects the outcome of the study; 5. Complicated with brain organic mental disorders, alcohol and drug dependence, schizophrenia, bipolar disorder, etc.; 6. Patients at risk of suicide; 7. Conditions that prevent patients from following and completing the study protocol (known drug and alcohol abuse, etc.); 8. Pregnant or lactating women; 9. The patient has a past allergy to this product; 10. Patients who experienced adverse events during the screening period were deemed unsuitable for inclusion in this study according to the investigator.

Design outcomes

Primary

MeasureTime frame
17-item Hamilton Depression Rating Scale;

Secondary

MeasureTime frame
Montgomery-Asberg Depression Rating Scale;Hamilton Anxiety Scale;

Countries

Chian

Contacts

Public ContactLe Yunyi

Tibet Autonomous Region People’s Hospital

leyunyi@bjmu.edu.cn+86 133 6662 1285

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026